跳转到主要内容
搜索

Bedi brings significant expertise in strategy, growth, and execution driving technology-enabled innovation across the healthcare industry

RADNOR, PA. – 2026 年 3 月 12 日 – Certara, Inc. (纳斯达克股票代码:CERT), a global leader in model-informed drug development, announced today the appointment of Arjun Bedi, a life sciences and digital transformation business leader with over 36 years of experience, to its Board of Directors, effective February 2026.

Bedi brings deep experience in strategic leadership, operational execution, and digital and AI-driven transformation across the health and life sciences industries. Over his 35 year career at Accenture, he held multiple senior leadership roles and served on the Global Management Committee, accelerating growth in the life sciences and biotech segments serving many of the world’s top pharmaceutical and biotech companies, and leading the firm’s Global Strategic Client Portfolio. He is also the founder of the annual Health & Life Sciences CEO Forum, now in its 15th year, which convenes CEOs from the top 20 healthcare companies to collaborate on industry strategy and execution best practices.

“Arjun is an excellent addition to Certara’s board, bringing a powerful combination of technology fluency, growth leadership, and board governance experience,” said Jon Resnick, Chief Executive Officer. “His decades of work with many of the world’s leading pharmaceutical and biotech organizations will be invaluable in supporting greater industry adoption of biosimulation to help speed innovative new medicines to patients.”

“Certara is uniquely positioned at the intersection of biosimulation, AI, and drug development. I’ve seen firsthand how AI-enhanced biosimulation technology can unlock greater certainty in drug development assets while enhancing their commercial performance and patient impact,” said Arjun Bedi. “I'm excited to join the board as Certara is poised for accelerated growth."

Visit this webpage to learn more about our leadership and board of directors.

关于Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. 其客户包括超 2,600 家生物制药公司、学术机构和来自 70 个国家的监管机构。了解更多信息,请访问 www.certara.com.cn。

Certara 联系人:

Sheila Rocchio
[email protected]

媒体联系人:

Alyssa Horowitz
[email protected]

Certara 正在彻底改变药物发现与开发进程

我们变革药物开发,造福人类。我们致力于为创新者、研究人员和监管专家提供量身定制的软件和服务解决方案,以满足他们的需求,从而在整个药物开发生命周期中取得成功。

了解更多信息

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software